Soleno's first wave of rare disease drug sales beats expectations
The first full quarter sales for Soleno Therapeutics’ rare disease drug Vykat XR are in, and they have exceeded investor forecasts.
Soleno said Thursday morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
